Trial Profile
safety and efficacy of recombinant human endostatin (endostar) administrated by durative infusion combined with chemotherapy within the vascular normalization period in treating advanced non-small cell lung cancer (NSCLC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2017
Price :
$35
*
At a glance
- Drugs Endostatin (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer